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mixture of acetonitrile and H 2 O each containing 0.1% trifluoroacetic acid. During purification, a gradient of 30% to 80% acetonitrile over 8 minutes was used with fraction collection triggered by UV detection (220 nM).
1 H spectra were recorded using either an Inova 400 MHz spectrometer (Varian) or an Inova 300 MHz spectrometer (Varian). Two LCMS methods were used to analyze samples' purity. Method 1: Agilent 1200 series LC/MS equipped with a Zorbax™ Eclipse XDB-C 18 reverse phase (5 micron, 4.6 x 150 mm) column having a flow rate of 1.1 mL/min. The mobile phase was a mixture of acetonitrile and H 2 O each containing 0.05% trifluoroacetic acid. A gradient of 5% to 100% acetonitrile over 8 minutes was used during analytical analysis. Method 2: Acquity HPLC equipped with a Waters BEH C18, 1.7 micron, 2.1 x 50 mm column; Column Temperature: 45 °C; Flow: 0.50 mL/min; Solvent A: 0.05% TFA in Water; Solvent B: 0.025% TFA in acetonitrile; Gradient: 2% to 100% Solvent B over 1.3 minutes; Run Time: 3 min.
General Synthetic Procedures
The following general procedures were used to synthesize compounds having different but analogous structures.
General procedure for the synthesis of diamine 6 (Method 1):
N Br A mixture of 2, 5-dibromopyridine (1a, 2.0 g, 8.4 mmol), pyridine (0.80 g, 10.1 mmol), and 1, 3-diaminopropane (10 mL) was refluxed for 18 hours. The reaction mixture was concentrated in vacuo and dissolved in 15 mL of anhydrous dichloromethane. The white precipitation was filtered off and the filtrate was concentrated to yield N 1 -(5-bromopyridin-2-yl)propane-1,3-diamine (3a, 1.6 g, 83%) as an oil, which was used directly for next reaction without further purification. A mixture of N 1 -(5-bromopyridin-2-yl)propane-1,3-diamine (3a, 5.0 g, 21.7 mmol) and triethylamine (2.6 g, 26 mmol) in anhydrous dichloromethane (50 mL) was slowly treated at 0 °C with trityl chloride (7.3 g, 26 mmol). After stirring at room temperature for 1 hour, the reaction mixture was washed with water (10 mL) for three times, dried over Na 2 SO 4 , filtered, and evaporated in vacuo. The residue was washed with methanol (50 mL×2) to afford N 1 -(5-bromopyridin-2-yl)-N 3 -tritylpropane-1,3-diamine (4a, 9.6 g, 79%) as a solid, which was used directly for next reaction without further purification. -tritylpropane-1,3-diamine (4a, 0.94 g, 2.0 mmol) in anhydrous tetrahydrofuran (10 mL) was treated at room temperature with LHMDS (6.0 mL, 1.0 M in tetrahydrofuran) under nitrogen atmosphere. After stirring at room temperature for half hour, another solution of 1-(bromomethyl)-4-chlorobenzene (2.05 g, 10 mmol) in 10 mL of anhydrous tetrahydrofuran was added slowly at room temperature to the reaction mixture. The resulting reaction mixture was stirred at room temperature for another hour after the addition was completed. Then, the mixture was poured into ice water (100 mL) and extracted with ethyl acetate (30 mL×3). The combined organic extracts were washed with water (20 mL), dried over Na 2 SO 4 , filtered, and concentrated. The crude product was further purified by silica column chromatography using hexanes/ethyl acetate (80:1) to yield N 1 -(5-bromopyridin-2-yl)-N 1 -(4-chlorobenzyl)-N 3 -tritylpropane-1, 3-diamine (5a, 0.60 g, 50%) . Cl N 1 -(5-Bromopyridin-2-yl)-N 1 -(4-chlorobenzyl)-N 3 -tritylpropane-1,3-diamine (5a, 597 mg, 1.0 mmol) was dissolved in dichloromethane/TFA (5.0 mL/ 5.0 mL). The reaction mixture was stirred at room temperature for 1 hour. Volatiles were removed under vacuum and the residue was dissolved in methanol (50 mL). The methanol solution was washed by hexanes (10 mL×10); and 1 M NaOH was added to the solution to adjust pH = 7-8. Then the aqueous phase was extracted with dichloromethane (10 mL×3). The combined organic extracts were dried over Na 2 SO 4 , filtered, and concentrated to yield N 1 -(5-bromopyridin-2-yl)-N 1 -(4-chlorobenzyl)propane-1,3-diamine (6a, 300 mg, 85% A mixture of 2,5-dibromopyridine (5.0 g, 20 mmol) and butane-1,4-diamine (27.8g, 310 mmol) was stirred at 155 °C for 3 hours. The reaction mixture was concentrated, dissolved in dichloromethane (50 mL), and filtered. The filtrate was evaporated to afford N 1 -(5-bromopyridin-2-yl)butane-1,4-diamine (3e, 5g, 97%) as an oil which was used directly in the next reaction without further purification. -(5-bromopyridin-2-yl)butane-1,4-diamine (3e, 5.0 g, 0.02 mmol) and triethylamine (2.48 g, 0.24 mmol) in tetrahydrofuran (20 mL) was treated at 0 °C with trityl chloride (5.4 g, 0.02 mmol) in several portions. After the addition was completed, the solution was stirred at room temperature for additional 1 hour. The reaction mixture was filtered; and the filtrate was evaporated to give N 1 -(5-bromopyridin-2-yl)-N 3 -tritylbutane-1,4-diamine (4e, 4.0 g, 80%). -tritylbutane-1,4-diamine (4e, 4g, 8.2 mmol) in anhydrous tetrahydrofuran (40 mL) was treated at room temperature with LHMDS (24.6 mL, 1.0 M in tetrahydrofuran) under nitrogen atmosphere. After stirring at room temperature for half hour, another solution of 1-(bromomethyl)-4-chlorobenzene (8.4g, 41.1 mmol) in 10 mL of anhydrous tetrahydrofuran was added slowly at room temperature to the reaction mixture. The resulting reaction mixture was stirred at room temperature for another hour after the addition was completed. Then, the mixture was poured into ice water (50 mL) and extracted with ethyl acetate (30 mL×3). The combined organic extracts were washed with water (20 mL), dried over Na 2 SO 4 , filtered, and concentrated. The crude product was further purified by silica column chromatography using hexanes/ethyl acetate (80:1) to yield N 1 -(5-bromopyridin-2-yl)-N chlorobenzyl)-N 3 -tritylbutane-1,4-diamine (5e, 3g, 60%) as a solid. Cl 5e (350 mg, 0.57 mmol) was dissolved in dichloromethane/TFA (4.0 mL/ 2.0 mL). The reaction mixture was stirred at room temperature for 2 hour. The pH of the mixture was adjusted to 9 using 4 M NaOH. The aqueous layer was extracted with dichloromethane (5.0 mL×3). The organic layers were combined, dried over Na 2 SO 4 , filtered and concentrated. The residue was purified by silica gel column chromatography (dichloromethane/MeOH=20:1) to afford 6e (100 mg, 50%) as an oil.
The compound was prepared according to general procedure for the synthesis of diamine 6 (Method 1).
1
H NMR (300 MHz, CD 3 OD) δ ppm 8.26 (d, J = 2.4 Hz, 1H), 7.39 (dd, J = 2.4 Hz, 9 Hz, 1H), 7.34-7.25 (m, 1H), 7.20 (d, J = 1.5 Hz, 1H), 6.95 (dd, J = 2.1 Hz, 8.4 Hz, 1H), 6.28 (d, J = 9 Hz, 1H), 4.53 (s, 2H), 3.70 (t, J = 7.3 Hz, 2H), 3.04 (t, J = 6.3 Hz, 2H), 2.11-2.07 (m, 2H).
The compound was prepared according to general procedure for the synthesis of diamine 6 (Method 1). The compound was prepared according to general procedure for the synthesis of diamine 6 (Method 1).
H NMR (300 MHz, CD 3 OD) δ ppm 8.11 (d, J = 2.4 Hz, 1H), 7.43 (dd, J = 3.0 Hz, 9.0 Hz, 1H), 6.37 (d, J = 9 Hz, 1H), 3.54 (t, J = 7.2 Hz, 2H),3.34 (t, J = 7.5 Hz, 2H), 2.71 (t, J = 6.6 Hz, 2H), 1.74-1.53 (m, 4H), 1.38-1.30 (m, 2H), 0.95 (t, J = 7.5 Hz, 
Cl Cl
The compound was prepared according to general procedure for the synthesis of diamine 6 (Method 1). 1 H NMR (300 MHz, CD 3 OD) δ ppm 8.16 (d, J = 2.4 Hz, 1H), 7.47 (dd, J = 2.4Hz, 9 Hz, 1H), 7.36 (d, J = 8.1 Hz, 1H), 7.29 -7.27 (m, 1H), 7.05-7.02 (m, 1H), 6.39 (d, J = 9 Hz, 1H), 4.72 (s, 2H), 3.57 (t, J = 6.9 Hz, 2H), 2.93 (t, J = 6.9 Hz, 2H); LCMS (ESI): m/z 376.29 (M + H + ).
General procedure for the synthesis of diamine 6 (Method 2): Propane-1,3-diamine (28 g, 0.38 mol) was placed in a flask and cooled with an ice-bath. Trityl chloride (7.0 g, 0.025 mol) was added to the flask in several portions. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated and treated with dichloromethane (50 mL). The suspension was filtered; and the filtrate was evaporated to afford N 1 -tritylpropane-1, 3-diamine (14, 7.9 g, 99%) .
-tritylpropane-1,3-diamine (14, 2.0 g, 6.3 mmol) in methanol (20 mL) was treated with 2-phenylacetaldehyde (0.76 g, 6.3 mmol). The mixture was stirred at room temperature for 2 hours, then treated with NaBH 3 CN (0.794g, 1.26 mmol) in portions. The reaction mixture was stirred at room temperature for overnight. After removing the solvent, water was added and the mixture was extracted with ethyl acetate (50 mL x 3). The organic layer was separated, dried over MgSO 4 , filtered, and concentrated. The residue was purified by silica-gel column chromatography (dichloromethane/MeOH=120:1 to 100:1) to afford N 1 -phenethyl-N 3 -tritylpropane-1,3-diamine (15b, 800 mg, 30%) as a solid. -(4-chlorophenethyl)-N 3 -tritylpropane-1,3-diamine (15a, 1.0 g, 2.2 mmol), 2,5-dibromopyridine (1.0 g, 4.4 mmol), Cs 2 CO 3 (1.43 g, 4.4 mmol), and DMF (4 mL) in a sealed tube was heated at 180 °C for 20 min under microwave irradiation. The reaction mixture was diluted with ethyl acetate (30 mL) and washed with water. The organic layer was separated, dried over MgSO 4 , filtered, and concentrated. The residue was purified by silica gel column chromatography (hexanes/ethyl acetate = 80:1) to afford 16a (400 mg, 30%) as a solid. A solution of 16a (400 mg, 0.65 mmol) in dichloromethane (3.0 mL) was treated at 0 °C with CF 3 COOH (3.0 mL). The reaction mixture was stirred at room temperature for 2 hours. The mixture was neutralized with 4 M NaOH until pH = 9 and extracted with dichloromethane (50 mLx3). The organic layers were combined, dried over Na 2 SO 4 , filtered and concentrated. The residue was purified by silica-gel column chromatography (dichloromethane/methanol = 20:1) to afford N 1 -(4-bromophenethyl)-N 1 -(5-chloropyridin-2-yl)propane-1,3-diamine (6m, 170 mg, 71%) as an oil. -tritylpropane-1,3-diamine (15b, 400 mg, 0.95 mmol), 2,5-dibromopyridine (677 mg, 2.85 mmol), Cs 2 CO 3 (617 mg, 1.9 mmol), and DMF (4.0 mL) in a sealed tube was heated at 180 °C for 20 min under microwave irradiation. The mixture was diluted with ethyl acetate (30 mL) and washed with water. The organic layer was dried over Na 2 SO 4 , filtered and concentrated. The residue was purified by silica-gel column chromatography (hexanes/ethyl acetate = 80:1) to afford 16b (230 mg, 42%) as a solid. A solution of 16b (230 mg, 0.4 mmol) in dichloromethane (3.0 mL) was treated at 0 o C with CF 3 COOH (3.0 mL). The reaction mixture was stirred at room temperature for 2 hours. The mixture was neutralized with 4 M NaOH until pH = 9. The mixture was extracted with dichloromethane (5.0 mL x 3). The organic layers were combined, dried over Na 2 SO 4 , filtered and concentrated. 
Cl
A mixture of N 1 -(5-bromopyridin-2-yl)-N 1 -(4-chlorobenzyl)-N 3 -tritylpropane-1,3-diamine (5a, 700 mg, 1.17 mmol), phenylboronic acid (250 mg, 2.0 mmol), Na 2 CO 3 (212 mg, 2.0 mmol), and Pd(PPh 3 ) 4 (70.0 mg) in ethanol/H 2 O (7.0 mL/ 2.0 mL) was heated to 100 °C for 2 hours. When the mixture was cooled, the product was precipitated from the reaction solution. The solid was filtered and dissolved in dichloromethane/TFA (10.0 mL/ 10.0 mL). The mixture was stirred at room temperature for 1 hour. Volatile was removed under vacuum and the residue was dissolved in methanol (50.0 mL). The methanol solution was washed by hexanes (10 mL × 3), concentrated to yield N 1 -(4-chlorobenzyl)-N 1 -(5-phenylpyridin-2-yl)propane-1,3-diamine as a crude product, which was used directly in the next reaction without further purification.
General procedure for the formation of thiourea and urea: A solution of 6 (0.16 mmol, 1 equiv) in dichloromethane (1.5 mL) was added 1,1'-thiocarbonyldiimidazole or 1,1'-carbonyldiimidazole (0.16 mmol, 1 equiv). The mixture was stirred at room temperature for 3 hours and then treated with another solution of 7 (0.16mmol, 1 equiv.) and DIPEA (0.08 mmol, 0.5 equiv) in CH 3 CN (1.5 mL). The reaction mixture was heated at 150 °C for 10 minutes under microwave irradiation. The mixture was concentrated, dissolved in 3.0 mL of dichloromethane, and treated at 0 °C with 3.0 mL of TFA. The mixture was stirred at room temperature for 2 hours. Volatile was removed and the residue was purified by HPLC to afford 8 (10-40%). 
1-(3-(1H-imidazol-5-yl)propyl)-3-(3-((5-bromopyridin-2-yl)(4-chlorobenzyl)amino)propyl)thiourea (8a)
N
1-(3-(1H-imidazol-5-yl)propyl)-3-(3-((5-bromopyridin-2-yl)(4-chlorobenzyl)amino)propyl)-1-methylthiourea (27)
1-(3-(1H-imidazol-5-yl)propyl)-3-(3-((5-bromopyridin-2-yl)(4-chlorobenzyl)amino)propyl)urea (8k)
Cl
1-(3-(1H-imidazol-5-yl)propyl)-3-(3-((5-phenylpyridin-2-yl)(4-chlorobenzyl)amino)butyl)thiourea (10)
1-(3-aminopropyl)-3-(3-((5-bromopyridin-2-yl)(4-chlorobenzyl)amino)propyl)thiourea (13a)
H
1-(3-(1H-imidazol-4-yl)propyl)-3-(3-((3,4-dichlorobenzyl)(pyridin-2-yl)amino)propyl)thiourea (8b)
1-(3-(1H-imidazol-4-yl)propyl)-3-butylthiourea
HPLC (method 1): t R = 3.23 min, UV 220 = 100%; MS (ESI): m/z 241.1 (M+H + ).
1-(3-(1H-imidazol-4-yl)propyl)-3-(3-(5-bromopyridin-2-ylamino)propyl)thiourea (8g)
HPLC ( A mixture of 6a (300 mg, 0.85 mmol), (Boc) 2 O (220 mg, 1.02 mmol), and triethylamine (103 mg, 1.02 mmol) in tetrahydrofuran (10 mL) was stirred at 30 °C for 3 hours. Volatile was removed and the residue was dissolved in anhydrous tetrahydrofuran and treated with sodium hydride (50.0 mg, 60%, 1.3 mmol) in one portion. The reaction mixture was heated to 60 °C for half hour and treated with iodomethane (600 mg, 4.2 mmol) with caution. The mixture was stirred at 60 °C for overnight, cooled to room temperature and poured into ice-water (20.0 mL). The aqueous phase was extracted with dichloromethane (10.0 mL×3). The combined organic layers were dried over Na 2 SO 4 , filtered, and concentrated to give crude 18 (350 mg). A mixture of crude 18 (350 mg) in TFA/tetrahydrofuran (4.0 mL/ 10.0 mL) was stirred at 30 °C for 5 hours. After the pH value of the reaction solution was adjusted to pH = 7-8 using 1 M of NaOH, the mixture was extracted with dichloromethane (20.0 mL×3). The organic layers were combined, dried over Na 2 SO 4 , filtered, and concentrated. The crude residue was purified by silica-gel column chromatography (dichloromethane/methanol = 40:1) to afford 19 (0.20 g, 54% for 4 steps). Propane-1,3-diamine (28 g, 0.38 mol) was placed in a flask, cooled with an ice-bath and treated with trityl chloride (7.0 g, 0.025 mol) in several portions. The mixture was stirred at room temperature for 2 hours. After removing solvent, the residue was treated with dichloromethane (50 mL). The mixture was filtered; and the filtrate was evaporated to afford 20 (7.9 g, 99%) as an oil. and Cs 2 CO 3 (510 mg, 1.57 mmol). The mixture was stirred at 100 °C for overnight. After removing solvent, the crude product was purified by silica gel column chromatography (hexanes/ethyl aceate = 80:1) to afford 22 (310 mg, 70 %). A solution of 22 (300 mg, 0.5 mmol) in dichloromethane (2.0 mL) was treated at 0 °C with CF 3 COOH (2.0 mL). After stirring at room temperature for 2 hours, the reaction mixture was neutralized using 4 M NaOH solution until pH = 9. The mixture was extracted with dichloromethane (5.0 mL×3). The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 20:1) to afford 23 (150 mg, 84%) as an oil. -(4-chlorobenzyl)propane-1,3-diamine (50 mg, 0.14 mmol), 4-(1-trityl-1H-imidazol-5-yl)butan-1-amine (50 mg, 0.14 mmol), 1,1'-thiocarbonyldiimidazole (25 mg, 0.14 mmol), DIPEA (9 mg, 0.07 mmol), dichloromethane (1.0 mL) and CH 3 CN (1.0 mL) in a sealed tube was heated at 125 °C for 10 min under microwave irradiation. After removing volatile, the crude product was dissolved in dichloromethane (2.0 mL) and treated at 0 °C with CF 3 COOH (2.0 mL). The reaction mixture was stirred at room temperature for 2 hours. After removing the solvent, the residue was purified by HPLC to afford 24 (6.0 mg, 8%) as an oil.
1-(3-(1H-imidazol-4-yl)propyl)-3-(3-(benzyl(5-bromopyridin-2-yl)amino)propyl)thiourea (8h)
Br
Synthesis
1-(3-(1H-imidazol-5-yl)propyl)-3-(3-((4-bromophenyl)(4-chlorobenzyl)amino) propyl) thiourea (24)
1 H NMR (300 
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Compounds 
All animal experiments were performed through CROs based on fee-for-services. Studies are in compliance with the relevant local laws and institutional guidelines.
In vivo pharmacokinetic profiles and parameters of NCGC00159568-03 (ML156, 8i) after an IP dose of 30 mg/kg in Male C57BL/6 Mice.
SUMMARY 2. CLINICAL OBSERVATION
In the PK studies of NCGC00159568-03, slight mobility reduction was observed in all 15 animals at 5 minutes after IP administration and lasted for about 15 minutes. The clinical observations were summarized in the 
Blood collection
The animals were anesthetized with isoflurane and restrained manually at the designated time points. Approximately 120 µL of blood samples were taken from the animals into K2EDTA tube via retro-orbital puncture. Blood samples were put on ice and centrifuged to obtain plasma sample (2000 g, 5 min under 4°C) within 15 minutes post sampling. Sample storage Plasma samples were stored at approximately -70 °C until analysis.
and disposition
The backup samples will be discarded after one month unless requested.
Data storage
All raw data will be kept electronically in the computers at ChemPartner for 2 years. 2) Add 0.255 mL of DMAC into the vial containing NCGC00159568-03, shake it for 1 min and then sonicate for 1 min.
Sampling design after IP administration
3) Add 0.255 mL of Solutol into the mixture, shake it for 1 min and then sonicate for 3 min.
4) Add 4.584 mL of 10 mM pH9.0 carbonate buffer into the mixture, shake it for 1 min and then sonicate for 1 min. For plasma samples: an aliquot of 30 µL plasma sample was partitioned by PPT using 0.15 mL ACN which contains IS (Testosterone, 10 ng/mL). The mixture was vortexed for 2 min and centrifuged at 12000 rpm for 5 min. An aliquot of 5 µL supernatant was injected for LC-MS/MS analysis.
For diluted samples: an aliquot of 20 µL plasma sample was added with 80 µL blank plasma to obtain the diluted plasma samples, and the sample dilution factor is 5. An aliquot of 30 µL of diluted plasma sample was partitioned by PPT using 0.15 mL ACN which contains IS (Testosterone, 10 ng/mL). The mixture was vortexed for 2 min and centrifuged at 12000 rpm for 5 min. This report describes the plasma, brain, liver and tail pharmacokinetic profiles of the NCGC00159568-04 following itraperitoneal administration after two doses (at interval 12 hours) in male Swiss Albino mice. The analytical procedure was as per Annexure V. Test compound concentrations in plasma, brain, liver and tail were determined by LC/MS/MS.
STUDY OBJECTIVE
The objective of this study was to determine the plasma, brain, liver and tail concentration of NCGC00159568-04 in male Swiss Albino mice after two doses (at interval 12 hours) of NCGC00159568-04 through intra-peritoneal route at 20 mg/kg and calculation of tissue to plasma ratio. 
MATERIALS & METHODS Study Design
Details of the formulations of test articles used
Test article NCGC00159568-04 was dissolved in DMA, TEG and Water for Injection in the ratio of 20:40:40, and vortexed. Formulation details are provided in Table IIIA in Annexure III.
Test Article Administration 5.1.1.1 Intra-Peritoneal administration NCGC00159568-04 was administered intra-peritoneally using 1 ml syringes (BD) fitted on top with 26 G needle at a dose level of 20 mg/kg at dose volume of 10 mL/kg. After administration, animals were placed back in their respective cages. After dosing of each animal, the experimenter documented the same in the Dosing and Sample collection sheet. All animals were observed for any abnormal behavioral signs exhibited after drug administration.
Blood samples & Organ Collection 5.6.1 Blood sample collection Each mouse was anesthized using Isoflurane. Blood was collected through a capillary, guided in retro-orbital plexus. The blood samples were collected in prelabeled Heparin coated tubes (BD, cat. No.365965). 0.3 mL of blood was collected from each mouse at their respective timepoints. After collection of blood samples at each time point, the blood samples were stored on wet ice prior to centrifugation. Blood samples were centrifuged within 15 minutes to separate plasma at 5000 rpm, 4 °C for 10 minutes. The plasma was separated and transferred to pre labelled tubes and promptly frozen at -80 ± 10 °C until bioanalysis. 5.5.2 Organ Collection (Brain, Liver, Tail) Immediately after blood withdrawal for PK estimation, in situ whole body perfusion was performed using chilled saline. The chest and abdomen of the mouse was exposed, the inferior venacava was cut and Intra-cardiac perfusion was performed through an insertion in the left ventricle. Perfusion for each mouse was followed by decapitation for brain collection. The skin over the cranium was incised and deflected. The head was flexed and a cut was made through the muscles and the spinal cord at the junction of the foramen magnum and atlas vertebra. A circumferential incision was carefully made in the cranium using a pair of small scissors. The roof of the cranium was lifted off to expose the meninges and brain. The meninges were removed carefully. Then holding the head with the nose pointing upward the anterior part of the brain was lifted to separate the brain. After brain collection, liver was excised from the body, carefully all the diaphragmatic and abdominal ligaments were cut using a pair of small scissors and liver was collected. After that, the tail was collected by severing from the point below the tail marking, using a 22 no. surgical blade mounted on 4 no. scalpel. Separated tissues were immediately weighed and instantly freezed at -80 ± 10 °C until homogenization. Individual data and details of dosing and sample collection times are given in Table 1 
RESULTS
In-Life Observation
Animals were found to be lethargic and listless at later time points (15, 17, 20 and 24 hrs) . There was ataxia evident in few animals of same groups. All other animals were found to be normal throughout the study period.
NCGC00159568-04 Intra-peritoneal administration
The pharmacokinetic profiles of the NCGC00159568-04 in male Swiss Albino mice after twice intraperitoneal administration at 12 hour interval of NCGC00159568-04 at 20 mg/kg dose are shown below. The liver to plasma ratios of NCGC00159568-04 is 63.31 (AUC last liver (ng*h/g) / AUC last Plasma (ng*h/ml).
6.3.4. Pharmacokinetic parameter of NCGC00159568-04 in tail following Intraperitoneal administration at dose rate of 20 mg/kg, twice at 12 hours interval.
NC-Not calculated
The tail to plasma ratios of NCGC00159568-04 is 1.77 (AUC last Tail (ng*h/g) / AUC last Plasma (ng*h/ml).
In conclusion, on oral administration of NCGC00159568-04, the exposure in liver is found to be more as compare to brain and tail. The tissue to plasma for liver is found to be high, followed by tail and brain. Under the experimental conditions of this study and with the formulations used the tissue to plasma ratio is shown in table below.
NCGC00159568-04
Brain to plasma ratio 0.08
Liver to plasma ratio 63.31
Tail to plasma ratio 1.77
TEST SYSTEM & ANIMAL HUSBANDRY
Animal care was in compliant with the Regulations of Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India.
Species/Strain
Adult healthy, male Swiss Albino Mice were procured from the National Institute of Nutrition, Hyderabad, India on 12/08/2010. All animals were acclimatized for a period of three days (27/08/2010 -29/08/2010) in the Animal House Facility at GVKBIO.
Housing
The mice were housed individually in clean sterilized individually ventilated cages with controlled environmental conditions (Temperature: 22 ± 3 °C, Relative humidity: 30-70%). Autoclaved clean paddy husk was used as bedding material. They were maintained on a 12 hour light / dark cycle.
Animal identification
Each mouse was uniquely identified by an assigned number on tail with permanent marker pen as per SOP-IPH-121 for animal identification.
Feed & Water
The mice were fed with certified rodent pellets ad libitum (VetCare Feeds, Banglore, 
SAMPLE COLLECTION AND PREPARATION
Blood sample collection
Each mouse was anesthized using Isoflurane. Blood was collected through a capillary, guided in retro-orbital plexus. The blood samples were collected in prelabeled Heparin coated tubes (BD, cat. No.365965) . 0.3 mL of blood was collected from each mouse at their respective timepoints. After collection of blood samples at each time point, the blood samples were stored on wet ice prior to centrifugation. Blood samples were centrifuged within 15 minutes to separate plasma at 5000 rpm, 4°C for 10 minutes. The plasma was separated and transferred to pre labelled tubes and promptly frozen at -80 ± 10 °C until bioanalysis.
Organ Collection (Brain, Liver, Tail) Immediately after blood withdrawal for PK estimation, in situ whole body perfusion was performed using chilled saline. The chest and abdomen of the mouse was exposed, the inferior venacava was cut and Intra-cardiac perfusion was performed through an insertion in the left ventricle. Perfusion for each mouse was followed by decapitation for brain collection. The skin over the cranium was incised and deflected. The head was flexed and a cut was made through the muscles and the spinal cord at the junction of the foramen magnum and atlas vertebra. A circumferential incision was carefully made in the cranium using a pair of small scissors. The roof of the cranium was lifted off to expose the meninges and brain. The meninges were removed carefully. Then holding the head with the nose pointing upward the anterior part of the brain was lifted to separate the brain. After brain collection, liver was excised from the body, carefully all the diaphragmatic and abdominal ligaments were cut using a pair of small scissors and liver was collected. After that, the tail was collected by severing from the point below the tail marking, using a 22 no. surgical blade mounted on 4 no. scalpel. Separated tissues were immediately weighed and instantly freezed at -80 ± 10 °C until homogenization.
Preparation of Tissues Homogenate
Brain, liver and tail samples were weighed and appropriate volume of ice cold homogenizing media (normal saline) was added. Brain, liver and tail samples were homogenized on ice with the Ultra Turrax homogenizer and volume was adjusted with homogenizing media to achieve 1 g of brain per 5 ml of homogenate. After homogenization, the brain, liver and tail homogenates were immediately frozen at -80° C until analysis. Sample dilution-Plasma 
LC/MS/MS PARAMETERS
Sample dilution-Brain
No dilution done
Sample dilution-Liver
Matrix-Blank liver homogenate Dilution factor-100
All time points-Group-1, 2 and 3
Sample dilution-Tail
Matrix-Blank tail homogenate Dilution factor-5
EXTRACTION PROCEDURE
Extraction Procedure (Preparation of STD and QC)
To 48µl of Blank plasma sample 2µl of Standard Solution was added, Vortexed ↓ 150 µl of Metaprolol was added ↓ Vortexed for 5 min at 2000 rpm ↓ Centrifuged at 13000 rpm for 5 min at 4 °C ↓ 
